LON:HIK - Hikma Pharmaceuticals Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Hikma Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 1,942.50 +3.50 (+0.18 %) (As of 01/28/2020 12:43 PM ET) Add Compare Today's Range 1,925.50Now: GBX 1,942.50▼ 1,956.5050-Day Range 1,874.50MA: GBX 1,958.39▼ 2,02952-Week Range 1,491.50Now: GBX 1,942.50▼ 2,212Volume169,533 shsAverage Volume822,138 shsMarket Capitalization£4.71 billionP/E Ratio13.05Dividend Yield1.42%BetaN/A ProfileAnalyst RatingsAdvanced ChartDividendInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals. Read More… Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:HIK Previous Symbol CUSIPN/A CIKN/A Webhttp://www.hikma.com/ Phone+44-20-73992760Debt Debt-to-Equity Ratio37.69 Current Ratio1.28 Quick Ratio0.78Price-To-Earnings Trailing P/E Ratio13.05 Forward P/E Ratio14.50 P/E GrowthN/A Sales & Book Value Annual Sales£2.14 billion Price / Sales2.20 Cash FlowGBX 142.26 per share Price / Cash Flow13.65 Book ValueGBX 756.30 per share Price / Book2.57Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees8,400 Outstanding Shares242,319,008Market Cap£4.71 billion Next Earnings Date2/27/2020 (Estimated) OptionableNot Optionable Receive HIK News and Ratings via Email Sign-up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter. LSE:HIK Rates by TradingView Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions What is Hikma Pharmaceuticals' stock symbol? Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK." How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals? Hikma Pharmaceuticals declared a dividend on Friday, August 9th. Stockholders of record on Thursday, August 22nd will be paid a dividend of GBX 0.14 per share on Monday, September 23rd. This represents a dividend yield of 0.59%. The ex-dividend date is Thursday, August 22nd. The official announcement can be seen at this link. View Hikma Pharmaceuticals' Dividend History. When is Hikma Pharmaceuticals' next earnings date? Hikma Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Hikma Pharmaceuticals. What price target have analysts set for HIK? 8 equities research analysts have issued twelve-month price targets for Hikma Pharmaceuticals' shares. Their forecasts range from GBX 1,350 to GBX 2,240. On average, they expect Hikma Pharmaceuticals' share price to reach GBX 1,853.33 in the next year. This suggests that the stock has a possible downside of 4.6%. View Analyst Price Targets for Hikma Pharmaceuticals. What is the consensus analysts' recommendation for Hikma Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Hikma Pharmaceuticals. Has Hikma Pharmaceuticals been receiving favorable news coverage? News coverage about HIK stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hikma Pharmaceuticals earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the next several days. View News Stories for Hikma Pharmaceuticals. Who are some of Hikma Pharmaceuticals' key competitors? Some companies that are related to Hikma Pharmaceuticals include Merck KGaA (MRK), Bausch Health Companies (BHC), Canopy Growth (WEED), Evotec (EVT), Aurora Cannabis (ACB), Aphria (APHA), Knight Therapeutics (GUD), Ecofibre (EOF), HLS Therapeutics (HLS), OrganiGram (OGI), ORGANIGRAM-TS (OGI), Hexo (HEXO), Next Science (NXS), HEXO (HEXO) and Benchmark (BMK). What other stocks do shareholders of Hikma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC). Who are Hikma Pharmaceuticals' key executives? Hikma Pharmaceuticals' management team includes the folowing people: Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 62)Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 61)Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 50)Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 47)Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D How do I buy shares of Hikma Pharmaceuticals? Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Hikma Pharmaceuticals' stock price today? One share of HIK stock can currently be purchased for approximately GBX 1,942.50. How big of a company is Hikma Pharmaceuticals? Hikma Pharmaceuticals has a market capitalization of £4.71 billion and generates £2.14 billion in revenue each year. Hikma Pharmaceuticals employs 8,400 workers across the globe.View Additional Information About Hikma Pharmaceuticals. What is Hikma Pharmaceuticals' official website? The official website for Hikma Pharmaceuticals is http://www.hikma.com/. How can I contact Hikma Pharmaceuticals? Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760. MarketBeat Community Rating for Hikma Pharmaceuticals (LON HIK)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 724 (Vote Outperform)Underperform Votes: 578 (Vote Underperform)Total Votes: 1,302MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HIK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/28/2020 by MarketBeat.com StaffFeatured Article: What are some reasons analysts would give stocks a buy rating?
